Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021051 (
immunodeficiency
)
71,517
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
beta-Lapachone
is an o-naphthoquinone found to have in vitro cytotoxicity in cancer cells, type I human
immunodeficiency
virus, and fungi. Analytical methods for evaluating beta-lapachone in biological fluids using high-performance liquid chromatography (HPLC) have not been published. The reversed-phase HPLC method described in this report utilizes liquid extraction of a 0.5-ml plasma sample with average recoveries of 67+/-10.8% and 70+/-10.3% for beta-lapachone and 3-hydroxy-beta-lapachone, respectively. Sensitivity of the assay using ultraviolet (UV) detection at 256 nm is 15 ng ml(-1) from a 100 microl injection. Plasma standards for beta-lapachone and 3-hydroxy-beta-lapachone are linear with no significant difference in slope between the compounds. The retention times of 2.7 min for 3-hydroxy-beta-lapachone and 5.9 min for beta-lapachone result in a clean separation permitting use of the same assay procedure without modification for both compounds. This assay offers the advantage that either beta-lapachone or 3-hydroxy-beta-lapachone can serve as the internal standard, depending on which compound is being analyzed.
...
PMID:Quantitation of beta-lapachone and 3-hydroxy-beta-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography. 918 98